# Independent clinical, editorial, and novelty review

Review date: 8 November 2026. Evidence snapshot reviewed: 31 October 2026.

This is an internal AI-assisted critical review, not external journal peer review or a clinician's validation. The reviewer inspected the current manuscript, template, refined proposal, novelty evidence report, literature matrix, and primary-source novelty notes. No new training or participant-level analysis was performed, and no protected identifiers are reproduced.

## Editorial decision

**Major revision of the narrative; substantial empirical work remains before a clinical prediction submission can be described as confirmatory.** The existing document is unusually candid about retrospective event availability, incomplete event capture, fixed-prediction intervals, and the reserved cohort. Those are strengths to preserve. Its greatest editorial weakness is that the main story is obscured by a 976-word literature paragraph and accumulated diagnostic history. Its most defensible current contribution is a comparator-dependent empirical result, with an audit trail. It does not establish a new knowledge-graph family, stable incremental benefit from recorded events, a general disadvantage of graphs, an effective warning system, or clinically faithful explanations.

The paper can be made substantially clearer and more complete as an exploratory development report now. Writing cannot replace the missing optimization, validation, clinical-operating-point, or author-declaration evidence. Missing evidence should be reported transparently and assigned a concrete completion gate.

## Rating scale and baseline ratings

Scores assess documentation quality within the exploratory scope, not probability of journal acceptance. A score of 1 means absent or seriously misleading; 2 means major reconstruction required; 3 means interpretable but materially incomplete; 4 means strong, with bounded revisions needed; 5 means complete and precise for the stated scope. Scores are reviewer judgments, not validated measures.

| Part | Baseline score / 5 | Strength | Main revision needed |
|---|---:|---|---|
| Title | 4 | Names T1D, temporal event graphs, and retrospective development | Name CGM-defined low glucose or comparator to prevent an assumed clinical warning endpoint; retain exploratory status |
| Abstract | 3 | Includes participants, outcome, key deltas, uncertainty, and limitations | At 367 words it exceeds common structured-abstract limits; objective emphasizes sequence/routing while the most stringent comparator is pooling; external CGM transfer appears only in conclusions |
| Introduction | 2 | Extensive, cautious prior-art boundary | Replace the 976-word citation paragraph with focused paragraphs; move detailed paper-by-paper differences and access caveats to supplement |
| Methods, clinical framing | 4 | Clear eligibility, coverage, deterministic edges, event values and availability assumption | Define intended scientific use and target population; foreground exploratory selection history; keep unexecuted protocol options out of executed methods |
| Results, editorial structure | 3.5 | Exact paired estimates and denominators, limitations retained | Lead with cohort/coverage and strict aligned-pooling comparison; historical sequence screens and auxiliary transfers should be clearly secondary |
| Discussion | 4 | Reasonable caution about comparator dependence and absent clinical utility | Reduce repeated limitations and offer a sharper mechanism discussion that distinguishes temporal alignment, event-conditioned message computation, fusion and optimization |
| Conclusions | 3.5 | Numerically accurate bounded statement | Shorten; do not conclude broad graph ineffectiveness or superiority; repeat only the central strict contrast |
| Clinical claims and terminology | 4.5 | Distinguishes any observed low from sustained/symptomatic events, warning time, and dose decisions | Make this boundary visible in title/abstract and preserve it everywhere; rename “recovery” rule as recent non-low eligibility |
| Novelty positioning | 3.5 | Rejects broad KG/graph/context novelty and cites close work | Distinguish candidate empirical contribution from certified novelty; report focused-search limits once, with full matrix in supplement |
| Author declarations and submission readiness | 2 | Missing facts are explicit rather than invented | Ethics/exemption, authorship, conflicts, funding, contribution roles, data terms, code release/license, AI disclosure approval remain author-dependent |
| Readability and presentation | 3 | Methods tables and quantitative comparisons are usable | A concise main text plus complete supplement is needed; repair bibliography order and unused entries; make figure captions self-contained |

No part receives 5 merely because a checker passes. A compliant report can transparently document an incomplete or high-risk study; reporting completeness and evidential maturity are separate dimensions.

## Essential corrections before final documents

### 1. Put the strict comparator at the center of the paper

The title/abstract objective currently emphasizes graph versus sequence and modality routing. The strongest current inference is that the tested graph does not beat time-aligned pooling under the executed fixed schedules. Present this as the **most stringent comparison in the current synthesis**, not retrospectively as an untouched prespecified primary experiment. The historical plan initially prioritized graph versus multimodal GRU; the stricter pooling control was added after development findings. Preserve that evolution explicitly.

A fair study can report an exploratory negative result. Do not use “equivalence,” “non-inferiority,” “no effect,” “graphs do not help,” or “clinical relations are unnecessary.” No equivalence margin, non-inferiority design, fit-level uncertainty analysis, or broad architecture search supports those claims.

### 2. Replace the introduction's citation inventory

The current main introduction contains a 976-word paragraph listing many adjacent papers, exact thesis scores, access restrictions, and repeated statements about what is not new. It reads as a rebuttal/search log, obscuring the research question. Use 4–5 paragraphs: clinical/problem boundary; relevant representation precedents; comparison confounding; data/availability challenge; study objective and exploratory scope. Place the detailed 70-record matrix, uncertain splits, embargo status and exact near-match comparison in the supplementary research record. Do not describe the targeted search as systematic.

### 3. Remove the external-transfer result from abstract conclusions

The abstract conclusions add DCLP3/DCLP5 CGM-logistic transfer although the abstract methods/results do not explain that analysis. It is ancillary and does not validate the event model. Remove it from the abstract or include it coherently in methods/results within a journal's word limit. Prefer a supplemental external-feasibility/CGM-transfer section that explicitly separates it from external graph validation.

### 4. Keep episode and warning terminology exact

The target is any one of six observed CGM readings below 70 mg/dL in the next 30 nominal minutes. It is neither a confirmed sustained episode nor a guaranteed 30-minute lead time. A positive can be driven by the +5-minute reading. Use “CGM-defined low-glucose risk” or “future low CGM” where precision matters. Symptoms and severe hypoglycemia were not measured. The last-three-non-low eligibility rule is not a clinical recovery definition. AP and Brier do not establish alert burden, sensitivity at an operating point, clinically useful lead time, or net benefit.

### 5. Describe the graph's actual semantics

The implemented edges assign an event to an observed later CGM bin under a deterministic time rule. They do not encode independently curated treatment relationships or causal physiological mechanisms. Modality routing is reconstructible from input types, and both generic/typed arms see modality indicators. “Temporal event graph” is accurate. “Clinical knowledge graph,” “clinically meaningful relations,” and “causal explanation” require additional definitions and validation that are absent.

### 6. Qualify the eight-epoch comparison correctly

The one-fold eight-epoch pair has a smaller difference than the two-epoch multi-fold summary, but it also differs in seed, fold composition versus an aggregate, and CPU/GPU execution. Do not write that extra epochs *caused* the gap to narrow, or that it proves convergence. It is a separate fixed-schedule sensitivity. A controlled learning-curve comparison at the same seed/fold/source/hardware would be stronger evidence for an epoch effect.

### 7. Maintain the distinction between reserved and untouched data

The manuscript correctly says that 183 participants were reserved for final model-performance evaluation while aggregate eligibility and label-coverage audits included them. Preserve that statement. Avoid the stronger description “wholly unopened/untouched cohort.” No performance scoring is documented; preprocessing summaries were inspected. Existing development folds were repeatedly inspected and informed model design, so they are not untouched nested cross-validation.

### 8. Repair reference mechanics

A local numbered-citation inspection found 44 bibliography entries, 39 cited in the body, and no missing numbered references. Uncited entries are [15], [16], [28], [29], and [38]. References are not ordered by first occurrence. Choose a journal style, renumber after editing, and either cite each retained main-text entry or move it to the supplementary matrix. References [35]–[40] lack blank paragraph separators in the Markdown, which merges them in the generated PDF. Avoid editorial comments such as “publisher inaccessible” in the final reference itself; retain those in the evidence ledger or footnotes.

### 9. Complete study description without inventing patient facts

The main text needs a compact cohort flow (919 roster → 851 CGM → 835 recorded-modality candidates → 652 development +183 reserved), a summary of source study setting/recruitment/monitoring dates where verified, a patient characteristics table if supported, and a statement explaining why the analysis size was determined by all available eligible participants. Millions of overlapping windows are not an independent sample-size justification. Missing demographics and subgroup results should remain visible limitations. Original-study cohort size 558 must not replace the released cohort counts.

### 10. Explicit author-dependent submission blockers

Resolve authors/affiliations/order, corresponding author, CRediT roles, local ethics/exemption determination, data-use and cloud processing permission, funding, conflicts, patient/public involvement, repository URL and archived version/license, and human approval of the AI-assistance disclosure. Original Loop approval cannot be asserted as local secondary-analysis approval. The AI disclosure should cover the assistance actually used across coding, execution, analysis, literature checking and drafting; do not imply all work was only a local Apple M4 run when the research history includes Kaggle/Colab and other execution paths.

## Proposed focused main-text structure

1. Structured abstract (roughly 250–300 words unless the chosen journal specifies otherwise).
2. Introduction (roughly 450–650 words): why event context matters, prior representations, why stricter controls are necessary, precise question.
3. Methods: design/selection history; cohort and data; outcome/information contract; models; fitting/selection; evaluation and statistics; ethics/reproducibility.
4. Results: cohort/coverage; strict graph-versus-pooling comparison and seed-level detail; eight-epoch sensitivity; historical sequence/routing/perturbation results as secondary context.
5. Discussion: principal finding; comparison with prior work; model/clinical interpretation; limitations; future validation.
6. Brief conclusion and complete declarations.
7. Supplement: stepwise project history, data audits, full model specifications, historical diagnostic tables, prior-art matrix, reporting checklist, experiment deviations, evidence/reproduction manifest and reviewer response.

A journal may allow a longer main paper; these word targets are editorial recommendations, not universal journal rules. No target journal has been specified.

## Suggested replacement title

**Temporal Event Graphs and Time-Aligned Pooling for CGM-Defined Low-Glucose Prediction in Type 1 Diabetes: An Exploratory Development Study**

This names the most informative contrast, precisely identifies the observed endpoint, and leaves the outcome to the results.

## Suggested replacement abstract

**Background:** Recorded insulin and carbohydrate events may contextualize continuous glucose monitoring (CGM), but an apparent graph advantage can reflect differences in temporal alignment or information fusion.

**Objective:** To compare temporal event message passing with non-graph representations under shared inputs, prediction windows, timing rules, and parameter budgets.

**Methods:** This exploratory retrospective analysis used the Loop public release. Development included 652 participants and 44,028,064 windows; 183 participants were reserved for later performance evaluation. Inputs comprised two hours of CGM and up to 64 recorded basal, bolus, and food events. The outcome was any observed CGM below 70 mg/dL in the next 30 minutes, conditional on recent non-low readings and complete future coverage. Events were replayed by occurrence time with immediate availability assumed. The strictest comparison evaluated 36,883-parameter graph and time-aligned pooling models over five participant-disjoint validation groups at two seeds for two epochs. A separate eight-epoch pair assessed one fold at another seed. Participant-macro average precision (AP) and Brier differences used participant bootstrap intervals conditional on fitted predictions.

**Results:** Pooling had higher AP in all ten two-epoch fold-seed fits and lower macro-Brier in nine. Averaging each participant's paired differences across seeds gave graph-minus-pooling AP −0.009900 (95% interval −0.010477 to −0.009345) and macro-Brier +0.0001264 (+0.0001096 to +0.0001429). The eight-epoch pair also slightly favored pooling. Earlier one-epoch comparisons favored the graph over a late-fusion sequence implementation; modality-specific routing showed mixed results.

**Conclusions:** The graph advantage depended on the comparator and did not persist against time-aligned pooling under the tested schedules. These exploratory findings concern specific implementations and do not establish warning utility, general graph ineffectiveness, or final generalization.

## Suggested replacement introduction

Continuous glucose monitoring (CGM) provides a detailed record of glucose exposure in type 1 diabetes (T1D). Predicting a future reading below 70 mg/dL may help characterize near-term risk, but a single low reading is distinct from a sustained or symptomatic hypoglycemic episode [1]. A model predicting a low within 30 minutes may identify a crossing only five minutes away. Predictive discrimination, warning lead time, and clinical usefulness therefore require separate evaluation.

Insulin delivery and carbohydrate records describe context that CGM alone cannot fully represent. Existing T1D studies already use this context in sequence models, engineered physiological summaries, and graph-based predictors [6–8,12,32,36]. Semantic patient-specific knowledge graphs have also been proposed [4,5], and temporally related diabetic event instances predate recent neural graph models [39]. Graphs, event inputs, patient-level evaluation, and explanation methods are consequently established ingredients. The narrower question is whether the way recorded event instances interact with CGM history improves prediction beyond models given the same information and timing.

This distinction matters because a graph-versus-sequence comparison can change several mechanisms simultaneously. A graph may align events to particular CGM bins before recurrent processing, while a sequence model may fuse event and CGM summaries only at the output. Differences in parameter count, chronological encoding, computation, or optimization can then be mistaken for evidence that graph relations add value. Parameter matching is useful but insufficient to identify the source of a performance difference. A control preserving event membership and event-to-time-bin assignment provides a more demanding test of the message-passing implementation.

The Loop public release offers substantial longitudinal CGM and recorded treatment-event data for such a comparison [2,3]. Repeated exports, conflicting measurements, incomplete event histories, and uncertain availability timestamps nevertheless require explicit preprocessing rules and common prediction windows. Event occurrence time alone does not establish when a record first became usable, and absence from the released history does not verify clinical absence.

We conducted an exploratory, retrospective development study comparing a temporal event-to-CGM graph with a parameter-matched late-fusion sequence model and a stricter time-aligned pooling control. We additionally examined modality-specific routing and bounded timing perturbations. The outcome was any observed CGM reading below 70 mg/dL within 30 minutes among eligible non-low indices with complete future coverage. The aim was to determine which tested representation choices account for differences under shared information and timing contracts. Final-holdout performance, independent external event-model validation, explanation faithfulness, and clinical warning utility remain outside the completed evidence.

## Revision acceptance criteria for this review

- The revised abstract follows the actual strict comparator, contains no orphan external-transfer conclusion, and stays within the selected journal's limit or an explicit provisional target.
- The main introduction has no literature-inventory paragraph and no universal novelty-absence claim.
- Most stringent contrast is clearly exploratory and added during development rather than retroactively preregistered.
- Each clinical term matches the observed threshold endpoint; no guaranteed warning time, symptoms, dosing benefit or causal semantics is implied.
- Graph-versus-pooling, graph-versus-sequence, event-input, perturbation and explanation screens have separate inference boundaries.
- The longer-schedule follow-up is not described as causal proof of a training-duration effect or convergence.
- Main-text references are cited and ordered, with detailed access limitations retained in a supplement.
- Missing declarations and empirical validations remain explicitly incomplete rather than hidden by a high manuscript score.

A second review should score revised files against these criteria and record residual limitations without inflating scientific readiness scores. Root synthesis should incorporate this review and any methods/statistics/reporting findings before packaging documents.

## Second independent review of the revised dossier

Re-review date: 8 November 2026. Inspected current generated manuscript, supplementary methods, master research record, submission-readiness register, and manuscript README after the major rewrite. PDF compilation/render inspection was pending at this re-review and is a separate delivery check.

### Verified improvements

- The title is now **Temporal Event Graphs and Time-Aligned Pooling for Hypoglycemia Prediction in Type 1 Diabetes: An Exploratory Patient-Disjoint Study**. It names the strict comparator and exploratory design. Adding “CGM-defined low glucose” would further refine endpoint specificity but is optional because the abstract/methods state the endpoint exactly.
- The abstract is 275 whitespace-delimited words, down from 367. Its objective and results now follow the strict pooling comparison; the orphan DCLP transfer conclusion has been removed. Selection on development results and absence of final performance are disclosed.
- The introduction is 458 words in five paragraphs. It now develops the problem, prior representations, strict comparison question, task-adjacent work and study aims. The previous 976-word source inventory is removed from the main narrative.
- The normalized main bibliography contains 32 references, all cited in the body, ordered by first appearance. No missing or unused main numbered reference was detected in the re-review.
- Results section 3.2 now leads with graph-versus-pooling, followed by the earlier graph-versus-sequence evidence. New cohort and pooling figures have meaningful captions and uncertainty boundaries.
- The revised methods/supplement explicitly state that pooling changes CGM processing even in event-empty bins. The strict contrast is consequently an implementation comparison rather than an isolated message-passing mechanism test.
- Source-study setting/dates are distinguished from the unverified released analytic population. Sample-size determination, unavailable subgroup data, automatic CGM outcome construction and observed-treatment context are explicit.
- The master record explains dataset roles, development evolution, metric correction, remote recovery, source mismatches and remaining evidence. The supplement supplies architecture, feature/scaling contracts, deviations and inference limits. The readiness register separates reporting, author facts and empirical claims.

### Before-and-after section ratings

These ratings concern the revised documentation within its exploratory scope. They do not certify clinical validity, completeness of author declarations, novelty, journal fit or acceptance.

| Part | Baseline / 5 | Revised / 5 | Evidence for change and residual limit |
|---|---:|---:|---|
| Title | 4 | 4.5 | Strict comparator and exploratory patient split named; precise CGM-low wording remains an optional refinement. |
| Abstract | 3 | 4.5 | Now 275 words with aligned objective/results and selection/availability caveats; chosen journal rules remain unconfirmed. |
| Introduction | 2 | 4.5 | Five focused paragraphs replace citation inventory; bounded novelty and prior-art references retained. |
| Methods, clinical framing | 4 | 4.5 | Added target-use, source/accrual distinction, automatic endpoint, sample-size explanation and complete pooling-path caveat; demographics/true analytic date bounds are absent. |
| Results, editorial structure | 3.5 | 4.0 | Strict contrast now first with cohort/pooling figures; one stale pooling-table cross-reference remains fixable at re-review. |
| Discussion | 4 | 4.0 | Comparison-specific limits are much stronger; one phrase still attributes the result to the message-passing operation rather than the whole tested implementation. |
| Conclusions | 3.5 | 4.0 | Bounded and numerically supported; can be shortened further for a selected journal. |
| Clinical terminology and claims | 4.5 | 4.5 | Any-low, future coverage, delayed availability, warning utility, causal semantics and explanation limits remain precise. |
| Novelty positioning | 3.5 | 4.5 | Clear task-specific exploratory contribution; no first-in-field claim or systematic-review pretense. |
| Author declarations / submission readiness | 2 | 2.5 | Missing facts now organized with explicit responsibilities; facts remain unresolved and scores cannot rise through writing alone. |
| Readability / presentation | 3 | 4.0 | Main structure/citations much clearer; spacing faults in newly synthesized companion documents need a final pass. |
| Complete-project synthesis (new deliverable) | Not separately rated | 4.5 content / 3.5 copyediting | Major stages, corrections and dataset roles synthesized with source links; several glued word/number strings need repair. |

### Residual fixable issues sent to the lead authoring agent

1. **Results table cross-reference:** Section 3.2 still says the pooling effects appear in “Tables 4 and 5,” although those tables are now numbered 2 and 3. Update the source template and rebuild.
2. **Message attribution:** Discussion says “argues against a benefit from the tested graph message-passing operation.” Replace with “tested graph implementation” or similarly bounded wording, retaining the explicit fusion/CGM-path caveat. The result cannot isolate the message operation.
3. **Primary-label consistency:** The limitations still refer to the “primary” graph-versus-pooling comparison. Use “more stringent” or explicitly label it the main contrast of the present synthesis; do not imply prospective specification before development.
4. **Companion-document copyediting:** Many source-number combinations lost a separating space, such as “Exactly70,” “All835,” “contributes44,028,064,” “uses650,” “with18.0182,” “complete70-record,” “matrix's70” and “first16.” Repair these throughout the master record, supplement, readiness register and README before rendering.
5. **Working bibliography count:** README says the complete working bibliography has 44 entries, while `references.bib` currently has 42 unique `@entry{key}` declarations. Correct or omit that count; the main bibliography correctly has 32 cited works.
6. **Author-request wording:** The readiness register says pending questions were requested from the author during preparation. Retain only if such a request was actually sent; otherwise state the facts remain to be supplied.
7. **AI-disclosure consistency:** Methods section 2.12 covers code, orchestration, local and remote execution. Acknowledgments still emphasize only the Apple M4 work. Harmonize them or refer the reader to 2.12, retaining author approval requirements.

These are bounded editorial repairs, not requests to launch additional training as part of a documentation task. The lead should verify their final state and current PDF/DOCX before packaging.

### Author-dependent or empirical gaps that remain visible

No AI-agent review can supply author identity/accountability, ethics or exemption, consent/data-use interpretation, conflicts, funding, contribution approval, patient involvement or a licensed immutable public code release. Cohort demographics, final-reserved performance, convergence/fair optimization, stable incremental event benefit, subgroup performance, real-time availability, alert burden/lead time, independent explanations and external graph validation remain empirically unresolved. The revised dossier appropriately records these limits. Their absence constrains submission scope and claim strength rather than making transparent exploratory documentation impossible.

The revised materials are substantially stronger and suitable for author review as a documented exploratory research dossier once the small fixable issues above are resolved. They should not be called a completed top-tier-journal submission, a clinically validated model, or an independently peer-reviewed manuscript.

## Final review of the compact journal-format manuscript

Re-review date: 8 November 2026. This pass supersedes the earlier rating table for the current compact main manuscript while retaining the earlier reviews as the revision history. The current working target is JAMIA, Research and Applications. The official-format source review and final rendering/packaging checks are separate from this clinical/editorial review.

### Current manuscript and independent checks

The main title remains **Temporal Event Graphs and Time-Aligned Pooling for Hypoglycemia Prediction in Type 1 Diabetes: An Exploratory Patient-Disjoint Study**. The author line now lists Pronab Chandra Roy and Lihui Liu in the supplied order. Institutional affiliation details are not fabricated; corresponding-author email, accountability, roles and approval remain explicit author responsibilities.

The current generated Markdown contains 4,865 whitespace-delimited words including title metadata, abstract, tables, references and figure legends. The structured abstract contains 220 words at this pass. Counting conventions differ from a journal's editorial word count, so the dossier's journal-format checker should calculate the exact excluded components. The main text has 32 numbered references; every entry is cited, every numeric citation resolves, and references follow ascending first appearance. Three numbered tables and two figures are present. The abstract now uses Objective, Materials and Methods, Results, Discussion and Conclusion headings.

The compact draft gives the strict pooling comparison priority and moves implementation, historical diagnostics, source-by-source prior art and deviations to the supplement/master record. It retains the crucial distinctions between the source-study cohort and released analytic cohort; any future low CGM and clinical hypoglycemic episodes; retrospective occurrence times and measured arrival times; parameter count and effective capacity; participant resampling and retraining uncertainty; model-performance reservation and earlier aggregate inspection; implementation comparisons and isolated message-passing effects. The old stale table numbering and overly specific message-operation attribution have been corrected.

The shorter discussion and conclusion convey the negative strict comparison without claiming equivalence, no clinical effect, graph-family inferiority, independently validated explanation, treatment benefit or novelty certification. The Methods disclosure now describes local/remote execution and AI assistance consistently with the research history. No newly invented ethics approval, funding, competing-interest, patient-involvement or author-contribution fact was found.

### Final documentation-quality ratings

The ratings below reflect the evidence and text available at this final pass. They are subjective internal editorial judgments on a five-point scale, not journal acceptance probabilities or clinical-validity scores. The baseline column refers to the initial 31 October draft reviewed above.

| Part | Initial / 5 | Current compact revision / 5 | Remaining limit |
|---|---:|---:|---|
| Title | 4 | 4.5 | Precise exploratory comparator framing; CGM-defined low-glucose wording would be an optional refinement. |
| Structured abstract | 3 | 4.5 | Clear result-centered 220-word structure; recommended small restoration of non-low/complete-future conditioning fits within 250 words. |
| Background and objective | 2 | 4.5 | Concise motivation, established prior art and bounded question; no systematic absence claim. |
| Methods and clinical framing | 4 | 4.5 | Core contracts and selection history are clear; full technical detail available in supplement. Actual cohort demographics/date bounds remain unavailable. |
| Results | 3.5 | 4.5 | Strict comparator first, exact effects/denominators and fixed-fit limits clear, auxiliary work scoped. No final generalization estimate exists. |
| Discussion | 4 | 4.5 | Comparison dependence, architecture path and optimization limits are explicit. Stronger mechanistic interpretation needs new controlled experiments. |
| Conclusion | 3.5 | 4.5 | Brief, bounded and supported by executed comparisons; no extrapolation to clinical utility. |
| Clinical claims and terminology | 4.5 | 4.5 | All completed evidence is retrospective sensor prediction; clinical episode/alert utility remains unestablished. |
| Novelty position | 3.5 | 4.5 | Specific auditable empirical contribution, established ingredients credited, first-in-field language avoided. Formal search completeness remains absent. |
| Declarations and author facts | 2 | 3.0 | Names supplied and accountability questions exposed; ethics/data-use/funding/interests/CRediT/PPI/email facts still require human confirmation. |
| Presentation and citations | 3 | 4.5 |32 cited/ordered main references;3 tables/2 figures and accessibility text. Final numerical-spacing and rendered-document checks remain delivery tasks. |
| Complete-project record and supplement | Not separately rated | 4.5 | History, corrections, dataset roles, technical contracts, deviations and limitations consolidated. Quality depends on final synchronized inventory/link/package verification. |

### Small corrections recommended before final rendering

1. Restore the abstract eligibility condition, for example: “after eligible non-low indices with complete future coverage.” This is important to the population on which the scores were evaluated and fits within the remaining abstract allowance.
2. Correct remaining figure-text spacing: Figure 1 alt text contains “shows919,” “participants,851,” “then652,” “contains44,028,064” and “and650”; Figure 2 caption contains “are95%.” These are copyediting defects, not statistical defects.
3. Synchronize the readiness table with current supplied facts. It still says no target and names not confirmed; state that JAMIA is the working target and author names/order were supplied, while authorship accountability, roles, corresponding-author details and final target approval remain pending. Supplement S8 should distinguish supplied names from formal approval rather than treating all identity fields as entirely unknown.
4. Maintain the journal-format word-count assessment as a reproducible check rather than describing the 4,865 total document tokens as the journal's main-text count.

These bounded corrections were sent to the lead agent. Final artifact checks should verify that they are applied to the source template and propagated to Markdown, DOCX and PDF. No additional model training is required to make this documentation accurate within its explicitly exploratory scope.

### Final disposition

**The compact manuscript is a substantially improved, coherent exploratory development paper, accompanied by a complete research-history and technical record.** Its editorial quality is high enough for serious author review once the small synchronized-document corrections and render checks are complete. This statement does not certify top-tier acceptance or submission readiness. Genuine remaining author facts, characterization, bias, optimization, calibration, alert, explanation and external-validation gaps are expressly documented and must constrain the intended claims and submission decision.
